|Bid||30.20 x 1200|
|Ask||40.50 x 1300|
|Day's range||29.30 - 33.97|
|52-week range||21.84 - 70.00|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021 - 12 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||63.25|
CAMBRIDGE, Mass., November 12, 2021--Scholar Rock today presented initial clinical data from Part A of its DRAGON Phase 1 proof-of-concept trial at the SITC Annual Meeting.
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., November 09, 2021--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.